Jenna Kopp
@JennaIBDnurse
Followers
139
Following
935
Media
3
Statuses
199
Director of Clinical Operations, Midwest GI Associates, Mom, Wife, IBD Nurse Practitioner and Patient Advocate
Omaha, NE
Joined August 2018
When it rains, it pours #IBD! FDA approves the second "in class" and first p19 IL-23 inhibitor for UC #colitis, #mirikizumab (Omvoh) based on results from the LUCENT phase-3 trials. 3 induction and monthly maintenance doses (300/200 mg)
nejm.org
Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial. We conducted two phase 3, randomized, double-blind, placebo-c...
2
9
34
Some initial thoughts post #UEGWeek2023 Risankizumab looks v good for Crohn's disease; impressive delta vs USTE across all primary and secondary endpoints • Lifting the therapeutic ceiling a little but hardly smashing through it • BUT ... multiple USTE biosimilars ready for
3
41
164
The current prior authorization process leads to unnecessary delays that is detrimental to patient care! We need prior authorization reform now! @IBDMD @DocCohenIBD @UChicagoIBD @UChicagoGI @CrohnsColitisFn #IBD
academic.oup.com
Lay Summary. Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type o
2
14
51
So exciting and so needed!
⭐️⭐️BIG win for our patients with stricturing Crohn’s disease⭐️⭐️ #STARconsortium is proudly supporting this trial. @ClevelandClinic is recruiting! @MRegueiroMD @BettenworthDb @Y_ECCO_IBD @vipuljairath @DavidBruiningMD @DCharabaty @EdwardLoftus2 @HelmsleyTrust @tinahamd @DrsMeena
0
1
2
While it is always exciting to have another option for patients, and Entyvio is a fabulous drug….this WILL result in increased delays in care as patients battle with PBM’s, maximizer/accumulator/alt funding plans (ALL which should be illegal!!)
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis | Business Wire
0
0
0
Sunday Review #IBD101 Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn’s Disease Therapeutic Outcomes Assessed Clinically and Endoscopically https://t.co/LOM4b94VN1
academic.oup.com
AbstractObjective. We postulated that adalimumab [ADA] drug clearance [CL] may be a more critical determinant of therapeutic outcome than ADA concentration
3
10
41
Check in regularly for more deep-dives on GI content! Remember to 🌟 like 🌟 retweet 🌟 follow 🌟 share
1
2
23
This 👇🏻 is what is harming patient care all around but especially in IBD where healthcare plan related delays in treatment or forced changes in regimens have serious consequences - immunogenicity, prolonged steroids, flares, increased healthcare utilization.
📝IMPORTANT ACG Survey Findings! New data gathered from ACG members on their #PriorAuthorization experience reveal #PriorAuth is ☑️Detrimental to patient care ☑️Overwhelming #Gastroenterology practices ☑️Harming patients Data: https://t.co/4vlijFs1oD
#FixPriorAuth #GItwitter
2
13
41
So thrilled to see even more expanded resources for brain-gut training! 👇👇👇
0
1
5
Everything you wanted to know about the basics of #IBD and #PSC with #MondayNightIBD #Back2Basics 📚 🔥 Join us tomorrow night with @ManuelBragaMD @MondayNightIBD #GITwitter
@MarcelYibirin @MondayNightIBD @yaransarkis @JHaydek @dunleavy_katie @ayshaslam999 @RomyChamoun @DCharabaty @GroverDheera @JosephHabibi_MD @Spencerkelley7 @KanikaGargMD @AmCollegeGastro @SharmeelKW @DrMTLong @ShimaghavimiMD @MarkPimentelMD @DrHarryThomas @drkeithsiau @AndrewCanakis @waqmd @AhmadBazarbashi @MayssanMuftah @SaqibWalayat @KeihanianTara @JamesHaddadMD @YousefElfanage2 @KiwanGIDoc @ZebaHussainiMD @MRegueiroMD @AGA_CGH @JHepatology @AASLDtweets @GregoryTBrennan 12/ #B2B #PSC #IBD Recap 🪁First sign: cholestatic liver enzymes 🪁Dx: MRCP 🪁ERCP if dominant strictures, r/o CCA 🪁CCA surveillance→ US/CT/MRI +/- CA19-9 q6-12mo 🪁PSC-IBD→ yearly colon surveillance at PSC dx 🪁Follow w LT regarding timing of LT #MondayNightIBD
0
4
17
#Diet & #IBD 🔺#CRAFT-UC: Remission rate in mild-mod UC w an anti-inflammatory diet (UC Exclusion Diet) vs FMT +/- UCED 🔺UCED alone gets🥇 🔺My💭: HighFiber LowMeat LowBadFat (LowDairy? Is LowFat🥛ok?) ▶️ healthy gut #microbiome 💭Diet is part of a MultiDimensional care to UC
RCT on diet in UC: Fecal transplantation with a novel diet for mild to moderate active ulcerative colitis.#ArieLevine
https://t.co/3bt8SEsgm6
@IBD_FloMD @fgomollon @ShomronH @Y_ECCO_IBD @GianlucaPellino @charlie_lees @IBD_JohnD @DCharabaty @IBD_Sir @NuhaZsurgeon
3
14
52
RCT on diet in UC: Fecal transplantation with a novel diet for mild to moderate active ulcerative colitis.#ArieLevine
https://t.co/3bt8SEsgm6
@IBD_FloMD @fgomollon @ShomronH @Y_ECCO_IBD @GianlucaPellino @charlie_lees @IBD_JohnD @DCharabaty @IBD_Sir @NuhaZsurgeon
0
15
35
Are we ready for combination of biologics or small molecules in #CrohnsDisease? Join us and #ScottDLee as we discuss treatment refractory #IBD @IBD_Afzali @FezaRemziMD @DCharabaty @moss_md @NMH_SHanauerMD #BrianFeagan Register 🆓️ #IBDHorizons2021
https://t.co/TMZsNAcF60 💻
0
1
6
Evaluation of Macrocytic anaemia (⬇️Hb, ⬆️MCV) 👇 Causes: ABCDEF A: Alcohol (and liver disease) B: B12 ⬇️ C: Compensatory reticulocytosis (haemolysis / blood loss) D: Drugs (e.g. MTX) / Dysplasia (of the bone marrow) E: Endocrine (⬇️thyroid) F: Folate ⬇️ / Fetus
2
17
97
Wondering about time required to achieve a response, remission or endoscopic healing in CD . Here are some best estimated time put forward by experts in STRIDE II publication @AmerGastroAssn @AmCollegeGastro @IbdClub @GiJournal @GIonDemand @MondayNightIBD
6
15
39
STRIDE-II: Here is a slide summary of Crohn's Disease Targets @IbdClub. By @IOIBD1 @IBDMD @ibddocmaria et al An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the … https://t.co/qRdqtRX4iJ
2
35
90